SCLERODERMA FOUNDATIONNEW ENGLAND INC (EIN 222603572) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1985

Legal Domicile

Principal Officer

ANNE SWEENEY

Phone

9786241254

Tax Period

2023-01-01 to 2023-12-31

SCLERODERMA FOUNDATIONNEW ENGLAND INC, founded in 1985, is a micro nonprofit that reported $17K in total revenue in fiscal year 2023. Revenue fell 92% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $6K, a strong 34% operating margin.

Mission

PROVIDE EDUCATIONAL AND EMOTIONAL SUPPORT TO PEOPLE WITH SCLERODERMA AND THEIR FAMILIES; TO STIMULATE AND SUPPORT RESEARCH DESIGNED TO IDENTIFY THE CAUSE AND CURE OF SCLERODERMA; AND TO

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $14,357

Program Service Revenue $0

Investment Income $0

Other Revenue $2,392

TOTAL REVENUE $16,749

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $2,836

Program Expenses $3,780

Other Expenses $11,040

TOTAL EXPENSES $11,040

Year-over-Year Comparison

	2023	2022	Change
Revenue	$16,749	$216,536	-0.9%
Expenses	$11,040	$163,041	-0.9%
Net Income	$5,709	$53,495	-0.9%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JANE LADAS	PRESIDENT	10.00	Officer Director	$0	$0	$0
ANDREA MAHONEY	VICE PRESIDENT	1.00	Officer Director	$0	$0	$0
ANTHONY CAPPELLUCCI	DIRECTOR	1.00	Director	$0	$0	$0
ELYSIA CAPPELLUCCI	DIRECTOR	1.00	Director	$0	$0	$0
ZAK KARSAN	DIRECTOR	1.00	Director	$0	$0	$0
SCOTT WINSLOW	DIRECTOR	1.00	Director	$0	$0	$0
CARLA KING	DIRECTOR	1.00	Director	$0	$0	$0
DAVID ROSENBERG	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2023	$16,749	$11,040	No data	$5,709
2022	$216,536	$163,041	$941,134	$53,495
2021	$295,424	$182,782	$981,565	$112,642
2020	$171,878	$193,132	$842,101	$-21,254
2019	$352,910	$320,764	$837,989	$32,146
2018	$350,335	$347,506	$710,223	$2,829

SCLERODERMA FOUNDATIONNEW ENGLAND INC